4th Annual Forum on Pharma & Biotech Patent Litigation 2013

Topics

• SPC references and recent opinion by the Advocate General: what you need to know to file your SPC applications
• The enforceability of gene sequence patents in light of HGS v Lilly
• The interplay between insufficiency of disclosure and future embodiments in biotech inventions
• EPO update on pharma and biotech patent litigation in Europe
• The impact of recent launch strategies by generics on evolving preliminary and interim injunctions across Europe
• The significance of case law developments across Eastern Europe and what they mean for your patent litigation strategies
• US developments in pharma and biotech patent litigation
• Successful strategy for pan-European patent enforcement following recent case law developments on cross-border injunctions
• The stem cell patent landscape
• How should you instruct scientific experts in your patent litigation proceedings in light of recent case law?
• Capitalising on research tool patents
• Commercial strategies to combat recent cross-border detention challenges
• Second medical use claims
• Disclosure of prior art and antitrust issues in the settlement of pharma patent disputes

Who should Attend

• Patent Attorneys
• In-House Counsel and Legal Directors
• Heads/Directors of Patents, Patent Counsel and Patent Managers
• Heads/Directors of IP, IP Counsel and IP Managers
• Attorneys specializing in IP and Patent Litigation and
• Patent Specialists/Experts
• Life Sciences/Pharma and Biotech